ST Pharm Seeks New Oligonucleotide CDMO Contracts at CPHI 2026

ST Pharm said on October 8 that it is participating in CPHI Worldwide 2026, the world's largest pharmaceutical exhibition, taking place in Milan, Italy, from October 6 to 8 (local time), where it is highlighting its core business of oligonucleotide CDMO (contract development and manufacturing).

ST Pharm is participating in CPHI Worldwide 2026, the world's largest pharmaceutical exhibition, taking place in Milan, Italy, from October 6 to 8 (local time). ST Pharm

At the event, ST Pharm is holding numerous business meetings with global pharmaceutical and biotech companies to strengthen cooperation with existing clients and explore new business opportunities.

To meet growing global demand for oligonucleotide CDMO services, ST Pharm has been ramping up operations this year at its Second Oligonucleotide Plant, completed last year. Equipped with production lines ranging from small and medium-sized to large-scale, the plant can meet clients' diverse production needs, from early-stage clinical development through commercialization.

Building on this production capacity and the quality competitiveness it has developed in global markets, ST Pharm plans to expand cooperation with existing clients while seeking to secure new ones.

ST Pharm also plans to meet with clients in its small-molecule API (active pharmaceutical ingredient) business to review the status of ongoing projects and discuss new projects and prospects for future business expansion.

An ST Pharm official said, "At CPHI Worldwide 2026, we are showcasing ST Pharm's oligonucleotide CDMO production capabilities and global competitiveness. Building on our RNA-based innovative technologies and CDMO capabilities, we will strengthen cooperation with our existing global partners and continue to expand opportunities for new business."

This content was produced with the assistance of AI translation services.